References
- ACTEMRA® (tocilizumab) injection, for intravenous or subcutaneous use. South San Francisco, CA: Genentech, Inc.; 2018.
- Lange J, Richard P, Bradley N. Usability of a new disposable autoinjector platform device: results of a formative study conducted with a broad user population. Med Devices. 2015;8:255–264.
- Callis Duffin K, Bukhalo M, Bobonich MA, et al. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. Med Devices. 2016;9:361–369.
- Bayas A, Ouallet JC, Kallmann B, et al. Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opin Drug Deliv. 2015;12:1239–1250.
- Paul C, Lacour JP, Tedremets L, et al. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol. 2015;29:1082–1090.
- Berteau C, Schwarzenbach F, Donazzolo Y, et al. Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteers. Patient Prefer Adherence. 2010;4:379–388.
- Limmroth V, Gerbershagen K. Single-use autoinjector for once-weekly intramuscular injection of IFNbeta-1a. Expert Opin Drug Deliv. 2014;11:1969–1978.
- Hupperts R, Becker V, Friedrich J, et al. Multiple sclerosis patients treated with intramuscular IFN-beta-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction. Expert Opin Drug Deliv. 2015;12:15–25.
- Guidance for Industry: statistical approaches to establishing bioequivalence. Rockville, MD: US Department of Health and Human Services; 2001 Accessed 2018 Nov 5. https://www.fda.gov/downloads/drugs/guidances/ucm070244.pdf
- Agency EM. Guideline on the investigation of bioequivalence. London, UK: European Medicines Agency Website; 2010. https://www.ema.europa.eu/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf. cited 2018 Nov 5
- Guidance for Industry and Food and Drug Administration Staff: applying human factors and usability engineering to medical devices. Rockville, MD: US Department of Health and Human Services; 2016 Accessed 2018 Nov 5. https://www.fda.gov/downloads/medicaldevices/./ucm259760.pdf
- Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324.
- Hochberg MC, Chang RW, Dwosh I, et al. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum. 1992;35:498–502.
- Li Z, Easton R. Practical considerations in clinical strategy to support the development of injectable drug-device combination products for biologics. MAbs. 2018;10:18–33.
- Guidance for Industry: bioavailability and bioequivalence studies submitted in new drug applications or investigtional new drug applications—general considerations. Rockville, MD: US Department of Health and Human Services;2014. Accessed 2018 Nov 5. https://www.gpo.gov/fdsys/pkg/FR-2014-03-18/pdf/2014-05849.pdf
- Chow SC. Bioavailability and bioequivalence in drug development. Wiley Interdiscipl Rev Computat Stat. 2014;6:304–312.
- Frey N, Grange S, Woodworth T. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis. J Clin Pharmacol. 2010;50:754–766.
- Borsci S, Buckle P, Hanna GB. Why you need to include human factors in clinical and empirical studies of in vitro point of care devices? Review and future perspectives. Expert Rev Med Dev. 2016;13:405–416.
- Domanska B, Stumpp O, Poon S, et al. Using patient feedback to optimize the design of a certolizumab pegol electromechanical self-injection device: insights from human factors studies. Adv Ther. 2018;35:100–115.
- Schiff M, Koo J, Jin E, et al. Usability and acceptability of the abatacept pre-filled autoinjector for the subcutaneous treatment of rheumatoid arthritis. Adv Ther. 2016;33:199–213.
- Allaert FA, Schueller R, Mabile F, et al. Human factors study of ZENEO® (needle-free autoinjector) and comparison of different user instruction formats. Panminerva Med. 2018;60:52–59.
- Brand-Schieber E, Munjal S, Kumar R, et al. Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients. Med Devices. 2016;9:131–137.